Candidemia in Colombia

Biomedica. 2020 Mar 1;40(1):195-207. doi: 10.7705/biomedica.4400.
[Article in English, Spanish]

Abstract

In Colombia, especially in intensive care units, candidemia is a frequent cause of infection, accounting for 88% of fungal infections in hospitalized patients, with mortality ranging from 36% to 78%. Its incidence in Colombia is higher than that reported in developed countries and even higher than in other Latin American countries. First, the patient’s risk factors should be considered, and then clinical characteristics should be assessed. Finally, microbiological studies are recommended and if the evidence supports its use, molecular testing. In general, American, Latin American, and European guides place the echinocandins as the first-line treatment for candidemia and differ in the use of fluconazole based on evidence, disease severity, previous exposure to azoles, and prevalence of Candida non-albicans. Taking into account the high incidence of this disease in our setting, it should be looked for in patients with risk factors to start a prompt empirical anti-fungal treatment.

En Colombia, especialmente en las unidades de cuidados intensivos, la candidemia es una causa frecuente de infección del torrente sanguíneo y representa el 88 % de las infecciones fúngicas en pacientes hospitalizados, con una mortalidad entre 36 y 78 %. Su incidencia en Colombia es mayor a la reportada en los países desarrollados e, incluso, en otros países de Latinoamérica. Para su manejo deben considerarse los factores de riesgo del paciente, luego valorar las características clínicas y, finalmente, hacer los estudios microbiológicos y, si es necesario, pruebas moleculares. En general, las guías estadounidenses, latinoamericanas y europeas recomiendan las equinocandinas como el tratamiento de primera línea de la candidemia y difieren en el uso de fluconazol dependiendo de la 'evidencia', la gravedad de la enfermedad, la exposición previa a los azoles y la prevalencia de Candida no albicans. Dada su gran incidencia en nuestro país, asociada con una elevada mortalidad, esta infección debe buscarse sistemáticamente en pacientes con factores de riesgo, con el fin de iniciar oportunamente el tratamiento antifúngico.

Keywords: Candidiasis; candidemia; intensive care units; mycoses; invasive fungal infections; Colombia.

MeSH terms

  • APACHE
  • Antifungal Agents / adverse effects
  • Antifungal Agents / pharmacology
  • Candida / classification
  • Candida / isolation & purification
  • Candidemia / diagnosis
  • Candidemia / drug therapy
  • Candidemia / epidemiology*
  • Candidemia / microbiology
  • Catheter-Related Infections / epidemiology
  • Catheter-Related Infections / microbiology
  • Colombia / epidemiology
  • Comorbidity
  • Drug Resistance, Fungal
  • Humans
  • Immunocompromised Host
  • Infant, Premature
  • Infant, Premature, Diseases / epidemiology
  • Neoplasms / epidemiology
  • Neutropenia / epidemiology
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / epidemiology
  • Opportunistic Infections / microbiology
  • Postoperative Complications / epidemiology
  • Postoperative Complications / microbiology
  • Prognosis
  • Renal Dialysis / adverse effects
  • Respiration, Artificial / adverse effects
  • Risk Factors
  • Species Specificity

Substances

  • Antifungal Agents